Central thromboxane A2, prostaglandin F2α, prostaglandin E, and prostaglandin D contribute to the cardiovascular effects elicited by nesfatin-1.
| Autor: | Güvenç Bayram G; Department of Physiology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkiye.; Department of Physiology, Faculty of Veterinary Medicine, Dokuz Eylül University, Kiraz, İzmir, Turkiye., Yalçin M; Department of Physiology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkiye. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Turkish journal of medical sciences [Turk J Med Sci] 2024 Mar 27; Vol. 54 (3), pp. 598-606. Date of Electronic Publication: 2024 Mar 27 (Print Publication: 2024). |
| DOI: | 10.55730/1300-0144.5827 |
| Abstrakt: | Background/aim: Our recent study revealed that the expression of lipoxygenase (LOX) and cyclooxygenase (COX) enzymes in the hypothalamus is activated by nesfatin-1, leading to the liberation of leukotrienes and prostaglandins (PG), respectively. Moreover, our prior report explained that intracerebroventricular (ICV) nesfatin-1 treatment triggers cardiovascular responses mediated by central LOX and COX enzymes. Building upon our prior reports, the present investigation sought to clarify the role of cardiovascularly active central COX products, such as thromboxane (TX) A2, PGF2α, PGE, and PGD, in orchestrating nesfatin-1-evoked reactions in mean arterial pressure (MAP) and heart rate (HR). Materials and Methods: The Sprague Dawley rats, which had guide cannula in the lateral ventricle for intracerebroventricular (ICV) injections and catheter in arteria femoralis for monitoring MAP and HR, were underwent central pretreatment with furegrelate (the TXA2 synthase inhibitor), PGF2α-dimethylamine (PGF2α-DA, the PGF2α receptor antagonist), or AH6809 (the PGE and PGD receptor antagonist), 5 min prior to ICV nesfatin-1 administration. The cardiovascular parameters were observed and recorded for 60 min posttreatment. Results: Nesfatin-1 induced cardiovascular responses in rats leading to pressor effect in MAP, and tachycardia following bradycardia in HR. Interestingly, ICV furegrelate, PGF2α-DA, or AH6809 pretreatment partially mitigated the cardiovascular effects revealed by nesfatin-1. Conclusion: The findings illuminate the role of nesfatin-1 in modulating MAP and HR through the central activation of specifically TXA2, PGF2α, PGE, and PGD from COX metabolites. Additionally, the study may also suggest the potential involvement of other central COX or LOX metabolites beyond these COX metabolites in mediating the cardiovascular effects produced by nesfatin-1. Competing Interests: The authors do not have any conflicts of interest to disclose. (© TÜBİTAK.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|